Description of what type of drug is Teritusumab/Telicat?

Teritusumab (Teclistamab-cqyv) is an innovative immune bispecific antibody drug for the treatment of relapsed or refractory multiple myeloma (RRMM). Different from traditional monoclonal antibody drugs, it targets two molecules at the same time: one end binds to the CD3 receptor on the surface of T cells, and the other end recognizes and binds to BCMA (B cell maturation antigen) on the surface of tumor cells. Through this "dual-target bridging" mechanism, teritusumab can allow T cells to accurately recognize myeloma cells, thereby activating the immune killing response and inducing tumor cell apoptosis.

The innovative significance of this drug mechanism is that it realizes a T cell activation method that "does not require exogenous immune cell transplantation". Compared with CAR-T therapy, teritusumab does not require genetic modification or cell reinfusion, so the treatment process is simpler and it is applicable to a wider range of people. Currently, the FDA approves this drug for the treatment of adult patients with multiple myeloma who have progressed after at least four therapies (including immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies).

From the perspective of pharmacological properties, teritusumab is a subcutaneous injection drug. It can effectively penetrate the bone marrow microenvironment and achieve tumor clearance through sustained activation of T cells. Pharmacokinetic studies show that the drug has a long half-life in the body and can maintain stable immune activity, making the treatment interval more flexible.

In clinical application, teritusumab has demonstrated strong and durable anti-tumor activity. Multiple overseas studies have shown that its monotherapy can significantly prolong progression-free survival (PFS) and achieve deep remission in some patients. Due to its unique immune mechanism, some patients can still maintain a long period of disease remission after stopping the drug.

In general, teritusumab is a pioneering bispecific antibody drug that belongs to the category of immune-targeted therapy. It represents a new trend in the treatment of multiple myeloma from traditional chemotherapy and monoclonal antibody therapy to "autoimmune remodeling" and is considered to be another major breakthrough after CAR-T.

Reference materials:https://www.tecvayli.com/